Spielberger Benedikt D, Zink Alicia, Rohr Jan C, Usadel Susanne, Klinker Hartwig, Freudenhammer Mirjam, Elling Roland, Rieg Siegbert, Henneke Philipp, Hufnagel Markus, Müller Matthias C
Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, Faculty of Medicine, University Medical Center, University of Freiburg, Freiburg, Germany.
Institute for Infection Prevention and Control, Faculty of Medicine, University Medical Center, University of Freiburg, Freiburg, Germany.
Sci Rep. 2025 Sep 18;15(1):32612. doi: 10.1038/s41598-025-20259-4.
Adherence to antiretroviral therapy (ART) and maintaining an undetectable maternal HIV viral load effectively prevent intrauterine and perinatal HIV transmission 1, 2. However, concerns remain regarding the safety of breastfeeding in infants exposed to maternal ART. This retrospective study analyzed eight breastfed HIV-exposed uninfected (HEU) infants who were followed from January 2015 to July 2022. Maternal ART regimens included abacavir/lamivudine (n = 2), tenofovir alafenamide/emtricitabine (n = 1) or tenofovirdisoproxil/emtricitabine (n = 5) in combinations with rilpivirine (n = 3) (RPV), dolutegravir (n = 2) (DTG), raltegravir (n = 1), darunavir/ritonavir (n = 1), or nevirapine (n = 1). Infants and mothers underwent sequential HIV-PCR testing, complete blood count, and ART drug monitoring in breast milk, infant serum, and maternal serum when available. The relative infant dose (RID) was calculated to assess drug exposure. Hematological parameters were compared with those of 62 HEU formula-fed infants from the same institution. No HIV transmission occurred. ART serum levels in breastfed infants varied significantly, with RPV and DTG levels above the adult target range in two cases. Notably, one infant had RPV levels exceeding the target RID by 633%, leading to cessation of breastfeeding. At four months, mean absolute neutrophil counts were lower in breastfed infants (1,130/µl) compared to formula-fed infants (2,000/µl), with the lowest individual absolute neutrophil counts in the formula-fed group. Despite ART levels above the adult target range in 3 infants, there was no consistent pattern between neutropenia and elevated ART levels. Our findings highlight the substantial variability in infant ART exposure during breastfeeding. Given this variability and the potential for drug accumulation in individual cases, maternal therapeutic drug monitoring should be considered to identify elevated levels early on. In such situations, infant monitoring tailored to the individual may also be warranted.
坚持抗逆转录病毒疗法(ART)并维持孕产妇艾滋病毒载量不可检测可有效预防宫内和围产期艾滋病毒传播1,2。然而,对于暴露于母亲ART的婴儿进行母乳喂养的安全性仍存在担忧。这项回顾性研究分析了2015年1月至2022年7月期间随访的8名母乳喂养的艾滋病毒暴露未感染(HEU)婴儿。母亲的ART方案包括阿巴卡韦/拉米夫定(n = 2)、替诺福韦艾拉酚胺/恩曲他滨(n = 1)或替诺福韦酯/恩曲他滨(n = 5),并与利匹韦林(n = 3)(RPV)、多替拉韦(n = 2)(DTG)、拉替拉韦(n = 1)、达芦那韦/利托那韦(n = 1)或奈韦拉平(n = 1)联合使用。婴儿和母亲在有条件时接受了连续的艾滋病毒PCR检测、全血细胞计数以及母乳、婴儿血清和母亲血清中的ART药物监测。计算相对婴儿剂量(RID)以评估药物暴露情况。将血液学参数与来自同一机构的62名HEU配方奶喂养婴儿的参数进行了比较。未发生艾滋病毒传播。母乳喂养婴儿的ART血清水平差异很大,有两例中RPV和DTG水平高于成人目标范围。值得注意的是,一名婴儿的RPV水平超过目标RID的633%,导致停止母乳喂养。在四个月时,母乳喂养婴儿的平均绝对中性粒细胞计数(1,130/µl)低于配方奶喂养婴儿(2,000/µl),配方奶喂养组中个体绝对中性粒细胞计数最低。尽管3名婴儿的ART水平高于成人目标范围,但中性粒细胞减少与ART水平升高之间没有一致的模式。我们的研究结果突出了母乳喂养期间婴儿ART暴露的巨大变异性。鉴于这种变异性以及个别情况下药物积累的可能性,应考虑进行母亲治疗药物监测以尽早发现水平升高的情况。在这种情况下,针对个体的婴儿监测也可能是必要的。